Ligand-based 3D-QSAR analysis and virtual screening in exploration of new scaffolds as Plasmodium falciparum glutathione reductase inhibitors
Tóm tắt
Plasmodium falciparum glutathione reductases involved in redox homeostasis pathway of parasite are found to be the most emerging target in the treatment of malaria. In the present study, a 3D-QSAR pharmacophore model was developed, based on twenty-three 1,4-naphthoquinone derivatives reported previously with marked inhibition against glutathione reductase (GR). The pharmacophore model development and 3D-QSAR analysis was carried out by PHASE program. The hypothesis with best survival score was found to be AAHRR. Thus the resulting pharmacophore model contained two aromatic rings, a hydrophobic and two hydrogen-bond acceptor sites. A statistically reliable model with good predictive power (r
2 = 0.8155, q
2 = 0.7054, average r
m
2
= 0.745) was obtained. Using these pharmacophore features, we screened a library of 214,029 compounds (Asinex Database) to find potential ligands that could inhibit the PFGR protein. The compounds then subjected to a number of filters of virtual screening workflow of Schrödinger software. Here, we report the best seven compounds based on their docking scores and mode of interactions. The aromatic ring, hydrophobic group and hydrogen-bond acceptor effects contribute to the inhibitory activity. Binding interaction of the inhibitors can further provide the information regarding the role of different features in ligands responsible for linkage with receptor. Both compound 1 and screened hit with highest docking score (lead-1) found to interact with ASN 278, LYS 32, GLU 31, GLU 277, ASP 275, THR 38, LYS 151 within same binding pocket of PFGR enzyme. The backbone structural scaffolds of these seven lead compounds obtained after screening could serve as building blocks when designing drug-like molecules for inhibition of P. falciparum GR.
Tài liệu tham khảo
ASINEX PHASE Database; (ASINEX DB_ligands, ASINEX DB_Flex) (2010) Schrödinger. LLC, New York
Becker K, Rahlfs S, Nickel C, Schirmer RH (2003) Glutathione-functions and metabolism in the malarial parasite Plasmodium falciparum. Biol Chem 384:551–566
Biot C, Bauer H, Schirmer RH, Davioud CE (2004) 5-Substituted tetrazoles as bioisosteres of carboxylic acids. Bioisosterism and mechanistic studies on glutathione reductase inhibitors as antimalarials. J Med Chem 47:5972–5983
Chang G, Guida WC, Still WC (1989) An internal-coordinate Monte Carlo method for searching conformational space. J Am Chem Soc 111:4379–4386
Davioud CE, Delarue S, Biot C, Schwobel B, Boehme CC, Mussigbrodt A, Maes L, Sergheraert C, Grellier P, Schirmer RH, Becker K (2001) A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J Med Chem 44:4268–4276
Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA (2006) PHASE: a new engine for pharmacophore perception, 3D-QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20:647–671
Gerard MD, Chaudiere J (1996) Metabolism and antioxidant function of glutathione. J Pathol Biol 44:77–85
Gilberger TW, Schirmer RH, Walter RD, Muller S (2000) Deletion of the parasite-specific insertions and mutation of the catalytic triad in glutathione reductase from chloroquine-sensitive Plasmodium falciparum 3D7. Mol Biochem Parasitol 107:169–179
Glide 5.6 (2010) Schrödinger. LLC, New York
Jorgensen WL, Maxwell DS, Tirado RJ (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225–11236
Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL (2001) Evaluation and reparameterization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 105(28):6474–6487
Kolossvary I, Guida WC (1996) Low mode search: an efficient, automated computational method for conformational analysis- application to cyclic and acyclic alkanes and cyclic peptides. J Am Chem Soc 118:5011–5019
Ligprep 2.4 (2010) Schrödinger. LLC, New York
MacroModel 9.8 (2010) Schrödinger. LLC, New York
Maestro 9.1 (2010) Schrödinger. LLC, New York
Meuller T, Johann L, Jannack B, Breuckner M, Lanfranchi DA, Bauer H, Sanchez C, Yardley V, Deregnaucourt C, Schrevel J, Lanzer M, Schirmer RH, Davioud CE (2011) Glutathione reductase-catalyzed cascade of redox reactions to bioactivate potent antimalarial 1,4-naphthoquinones—a new strategy to combat malarial parasites. J Am Chem Soc 133:11557–11571
Muller S (2004) Redox and antioxidant systems of the malaria parasite Plasmodium falciparum. Mol Microbiol 53:1291–1305
Muller S, Gilberger TW, Krnajski Z, Liiersen K, Meierjohann S, Walter RD (2001) Thioredoxin and glutathione system of malaria parasite Plasmodium falciparum. Protoplasma 217:43–49
Ojha PK, Mitra I, Das RN, Roy K (2011) Further exploring r 2m metrics for validation of QSPR models dataset. Chemom Intell Lab Syst 107:194–205
Pastrana MR, Dinglasan RR, Franke FB, Vega RJ, Fuentes CM, Baerga OA, Coppens I, Jacobs LM, Janse CJ, Serrano AE (2010) Glutathione reductase-null malaria parasites have normal blood stage growth but arrest during development in the mosquito. J Biol Chem 285:27045–27056
Phase 3.2 (2010) Schrödinger. LLC, New York
Protein Preparation Wizard (2010) Schrödinger. LLC, New York
Repasky MP, Shelley M, Friesner RA (2007) Flexible ligand docking with Glide. Curr Protoc Bioinform 18:8.12.1–8.12.36
Roy K, Mitra I, Kar S, Ojha P, Das RN, Kabir H (2012) Comparative studies on some metrics for external validation of QSPR models. J Chem Inf Model 52:396–408
Sharma GN, Savvides SN, Becker K, Schirmer M, Schirmer RH, Karplus PA (2003) Glutathione reductase of the malarial parasite Plasmodium falciparum: crystal structure and inhibitor development. J Mol Biol 328:893–907
Vega RJ, Franke FB, Dinglasan RR, Janse CJ, Pastrana MR, Rodriguez OJF, Jacobs LM, Serrano AE, Waters A, Srinivasan P (2009) The glutathione biosynthetic pathway of Plasmodium is essential for mosquito transmission. PLoS Pathog 5:2
Virtual Screening Workflow (2010) Schrödinger. LLC, New York